The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Jiangsu Hengrui Medicine
Stock and Other Ownership Interests - Jiangsu Hengrui Medicine
Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: Updated results from a multicenter, open label phase II trial.
 
Lin Shen
Consulting or Advisory Role - Jiangsu Hengrui Medicine
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Zhi Peng
No Relationships to Disclose
 
Yan-Qiao Zhang
No Relationships to Disclose
 
Jia Wei
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose
 
Jieer Ying
No Relationships to Disclose
 
Yanhong Deng
No Relationships to Disclose
 
Kangsheng Gu
No Relationships to Disclose
 
Ying Cheng
No Relationships to Disclose
 
Xianglin Yuan
No Relationships to Disclose
 
Juxiang Xiao
No Relationships to Disclose
 
Linna Wang
Employment - Jiangsu Hengrui Medicine
 
Jianjun Zou
No Relationships to Disclose